These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. In Situ Programming of CAR T Cells. Parayath NN; Stephan MT Annu Rev Biomed Eng; 2021 Jul; 23():385-405. PubMed ID: 33863239 [TBL] [Abstract][Full Text] [Related]
6. CAR T cells for solid tumors - developments to watch in 2023. Trefny MP; Kobold S Expert Opin Biol Ther; 2024 Apr; 24(4):207-211. PubMed ID: 38526025 [No Abstract] [Full Text] [Related]
7. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. Liu J; Zhou G; Zhang L; Zhao Q Front Immunol; 2019; 10():456. PubMed ID: 30941126 [TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside. Rodriguez-Cartagena LG; Bowles BS; Kurani SS; Windebank AJ; Kenderian SS; Greenberg-Worisek AJ Clin Transl Sci; 2018 Nov; 11(6):537-539. PubMed ID: 30242965 [No Abstract] [Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures. Fu M; Tang L Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615 [TBL] [Abstract][Full Text] [Related]
10. Standardizing CAR-T therapy: Getting it scaled up. Dai X; Mei Y; Cai D; Han W Biotechnol Adv; 2019; 37(1):239-245. PubMed ID: 30543841 [TBL] [Abstract][Full Text] [Related]
11. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Lee YH; Kim CH Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661 [TBL] [Abstract][Full Text] [Related]
12. CAR T cells: continuation in a revolution of immunotherapy. Singh AK; McGuirk JP Lancet Oncol; 2020 Mar; 21(3):e168-e178. PubMed ID: 32135120 [TBL] [Abstract][Full Text] [Related]
13. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. Ti D; Niu Y; Wu Z; Fu X; Han W Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005 [TBL] [Abstract][Full Text] [Related]
14. Beginning the CAR T cell therapy revolution in the US and EU. Grupp S Curr Res Transl Med; 2018 May; 66(2):62-64. PubMed ID: 29656949 [No Abstract] [Full Text] [Related]
15. CAR T cells - what have we learnt? Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589 [No Abstract] [Full Text] [Related]
16. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers. Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664 [TBL] [Abstract][Full Text] [Related]
17. Advances in off-the-shelf CAR T-cell therapy. Benjamin R Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953 [No Abstract] [Full Text] [Related]
18. CAR T-cells: A John von Neumann legacy? Quesnel B Curr Res Transl Med; 2018 May; 66(2):35-36. PubMed ID: 29685844 [No Abstract] [Full Text] [Related]
19. CAR T-cells for relapsed B-cell ALL in adults. Gilbert JA Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915 [No Abstract] [Full Text] [Related]